Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT

Thomas R Lynch,1* Roelie J Hempel,1 Ben Whalley,2 Sarah Byford,3 Rampaun Chamba,4 Paul Clarke,5 Susan Clarke,6 David Kingdon,7 Heather O’Mahen,8 Bob Remington,1 Sophie C Rushbrook,6 James Shearer,3 Maggie Stanton,9 Michaela Swales,10 Alan Watkins11 and Ian T Russell11

1Department of Psychology, University of Southampton, Southampton, UK
2School of Psychology/Cognition Institute, Plymouth University, Plymouth, UK
3King’s Health Economics, King’s College London, London, UK
4Member of Trial Management Committee responsible for Public and Patient Involvement, Bilston, UK
5Institute for Social and Economic Research, University of Essex, Colchester, UK
6Intensive Psychological Therapies Service, Dorset HealthCare University NHS Foundation Trust, Poole, UK
7School of Medicine, University of Southampton, Southampton, UK
8Psychology, University of Exeter, Exeter, UK
9Psychological Services, Southern Health NHS Foundation Trust, Winchester, UK
10School of Psychology, Bangor University, Bangor, UK
11Medical School, Swansea University, Swansea, UK

*Corresponding author t.lynch@soton.ac.uk

Declared competing interests of authors: Thomas R Lynch reports grants from the University of Southampton during the conduct of the study and personal fees from New Harbinger Publications and R.O.B.T Ltd outside the submitted work. Roelie J Hempel is co-owner and director of Radically Open Ltd. No money was exchanged between Roelie J Hempel and the company before, during or immediately after the study. David Kingdon reports grants from the National Institute for Health Research Efficacy and Mechanism Evaluation programme during the conduct of the study. Heather O’Mahen reports personal fees from the Charlie Waller Institute and personal fees from Increasing Access to Psychological Therapies outside the submitted work and reports being a member of the Guidelines Development Group National Institute for Health and Care Excellence (NICE) 2014 Antenatal and Postnatal Mental Health, an executive member of the British Psychological Society Perinatal Faculty, a NICE expert advisor for the Centre for Clinical Practice and a member of the Clinical Reference Group for Perinatal Mental Health. Maggie Stanton reports personal fees from British Isles DBT Training, personal fees from Stanton Psychological Services Ltd and personal fees from the Routledge, Taylor and Francis Group outside the submitted work. Michaela Swales reports personal fees from British Isles DBT Training and personal fees from Guilford Press, Taylor and Francis and Oxford University Press outside the submitted work. Ian T Russell reports grants from Health and Care Research Wales during the conduct of the study.
Scientific summary

The RefraMED RCT
Efficacy and Mechanism Evaluation 2018; Vol. 5: No. 7
DOI: 10.3310/eme05070

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Major depressive disorder is a disabling condition causing substantial impairment in psychosocial functioning and quality of life – in the workplace, at home and with friends. Only two-thirds of patients respond to antidepressant medication (ADM) and only half respond to psychological treatment. Thus, treatment resistance is a common outcome in major depression. The personal, social and economic burden of depression is substantial, especially for treatment-resistant depression.

Research on psychological interventions for refractory depression, defined as chronic depression or recurrent depression with two or more previous episodes, is sparse; most studies focus on acute or episodic depression and pharmacological or somatic treatments. Historically, psychotherapy trials avoided patients with refractory depression because these treatments were not designed to meet their needs. More recently, treatments that were developed specifically for refractory depression have achieved small to moderate effect sizes.

One potential reason why treatments work for only some patients with refractory depression is comorbidity with other mental disorders, especially personality disorders (PDs). Current treatments neglect the role of emotional overcontrol in refractory depression. However, many adults with chronic depression show overcontrolled traits, including greater self-criticism, impaired autonomy, rigid internalised expectations, excessive control of spontaneous emotion and inordinate fear of making mistakes. Radically open dialectical behaviour therapy (RO DBT), a novel transdiagnostic psychotherapy, aims to address this rigid coping style and the associated emotional loneliness. Earlier versions of RO DBT showed promise in two small randomised trials of patients with refractory depression and comorbid PDs.

Objectives

The primary objective of this trial was to estimate the efficacy of RO DBT plus treatment as usual (TAU) for refractory depression compared with TAU alone. The relative cost-effectiveness of RO DBT plus TAU compared with TAU alone was also estimated. Furthermore, the study aimed to explore the mechanisms of RO DBT treatment and moderators of treatment efficacy using novel statistical methods that exploit instrumental variables. These novel statistical methods aim to ameliorate bias caused by unobserved confounding, which can distort conventional analyses.

Methods

The Refractory depression: Mechanisms and Efficacy of RO DBT (RefraMED) trial was a multicentre, parallel-group, randomised trial in which participants were randomised to receive either 7 months of RO DBT plus TAU or TAU alone. RO DBT comprised 29 weekly individual sessions lasting 1 hour and 27 weekly skills classes lasting 2.5 hours. Patients allocated to TAU could access any treatment offered by the NHS or privately.

Participants were recruited from three secondary care NHS organisations in the UK: in Dorset, Hampshire and North Wales. Patients were eligible if they were aged ≥ 18 years, had a Hamilton Rating Scale for Depression (HRSD) score of at least 15 points, had a current diagnosis of major depressive disorder in the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I, were suffering either refractory or chronic depression and, in their current episode, had taken an adequate dose of ADM for at least 6 weeks without relief. Patients were excluded who met...
criteria for dramatic-erratic PD (cluster B), bipolar disorder or psychosis or who had a primary diagnosis of substance dependence or abuse.

Once eligibility was confirmed and consent received, the Swansea Trials Unit used an adaptive algorithm to allocate participants at random to treatments and therapists. Three stratifying variables were used to ensure that there was balance between groups: (1) early or late onset of depression, (2) a HRSD score of < or > 25 points and, presence or absence of PDs. Trained assessors, who were blind to these allocations, assessed participants at 7, 12 and 18 months after randomisation. The primary outcome measure was the severity of depressive symptoms, as measured by the HRSD, at 12 months.

To aid interpretation of the primary outcome, the number of patients achieving a ‘meaningful’ reduction in symptoms was estimated, and full and partial depression remission rates were computed for each group. These remission criteria accounted for both depressive symptoms (evaluated using the HRSD) and quality of life [evaluated using the Longitudinal Interval Follow-up Evaluation – Range of Impaired Functioning Tool (LIFE-RIFT)]. Other secondary outcome measures included suicidal ideation and behaviour. The cost-effectiveness of RO DBT was estimated by cost per quality-adjusted life-year (QALY). Causal analyses were conducted to explore the mechanisms by which RO DBT changes prognosis.

**Results**

In the trial a total of 250 participants were allocated by adaptive randomisation: 162 participants to RO DBT plus TAU and 88 participants to TAU. Patients reported substantial comorbidity: 96% met the criteria for at least one comorbid disorder, 86% for at least one DSM-IV Axis-I disorder and 78% for at least one DSM-IV Axis-II disorder. A total of 183 patients (73%) after 7 months, 190 (76%) patients after 12 months and 167 (67%) patients after 18 months provided data on the primary outcome. There was no significant difference between treatment groups in the proportion of participants who contributed data to the analysis.

The trial did not show a statistically significant difference between RO DBT and TAU for the primary outcome at 12 months. By 7 months, RO DBT had substantially and significantly reduced depressive symptoms relative to TAU by 5.40 HRSD points [standardised mean difference 1.03, 95% confidence interval (CI) 0.94 to 9.85 points; \( p = 0.02 \)]. Although this advantage for RO DBT continued, the reduction was no longer statistically significant at 12 months (2.15 HRSD points, standardised mean difference 0.41 points; 95% CI –2.28 to 6.58 points; \( p = 0.29 \)) or at 18 months (1.69 HRSD points, standardised mean difference 0.32 points, 95% CI –2.84 to 6.22 points; \( p = 0.42 \)). However, the TAU group achieved surprising improvements from month 12.

Full remission rates were low in both groups: 1%, 8% and 7% for the RO DBT group and 0%, 0% and 1% in for TAU group at 7, 12 and 18 months, respectively. Partial remission rates were higher in the RO DBT group participants (23%, 26% and 33% at successive assessments) than in the TAU participants (6%, 22% and 24% at successive assessments). Other indicators of improvement also showed superiority for RO DBT. The proportion of participants achieving a ‘reliable improvement’ or a ‘worthwhile’ change from the participants’ perspective – at least a 17.5% reduction in symptoms – was consistently higher for RO DBT group participants than for TAU group participants. To aid patients and clinicians in future treatment choices, and to set realistic expectations for probable outcomes, data were simulated from the primary outcome model. It was found that for every 100 new patients, 32 would experience ‘worthwhile’ improvements in symptoms after 12 months by choosing RO DBT rather than TAU.

We found significant advantages for RO DBT participants in both emotional approach coping [as assessed by the Emotional Approach Coping scale (EAC)] and psychological inflexibility [as assessed by the Acceptance and Action Questionnaire (AAQ-II)] throughout the trial. In the RO DBT group participants, the EAC mean score and the standardised mean difference between groups increased over time at month 7 by 1.50 EAC points (standardised mean difference 0.32 points, 95% CI 0.09 to 2.90 points; \( p < 0.05 \)); at month 12 by 3.55 EAC points (standardised mean difference 0.76 points, 95% CI 2.14 to 4.95 points; \( p < 0.001 \)); and
at month 18 by 2.98 EAC points (standardised mean difference 0.64 points, 95% CI 1.14 to 4.82 points; 
\( p < 0.01 \)). The mean AAQ-II scores decreased over time and all standardised mean differences were 
medium to large (month 7: –3.37 AAQ-II points, standardised mean difference 0.49 points, 95% CI –5.92 to 
–0.82 points; \( p = 0.01 \); month 12: –4.94 AAQ-II points, standardised mean difference 0.72 points; 95% CI 
–7.53 to –2.36 points; \( p < 0.001 \); and month 18: –5.48 AAQ-II points, standardised mean difference 
0.79 points, 95% CI from –8.74 to 2.22 points; \( p = 0.001 \)). However, we found no significant advantage 
for RO DBT group participants in impaired functioning (as assessed by the LIFE-RIFT), suicide ideation scores 
[as assessed by the Modified Scale for Suicidal Ideation (MSSI)] or perceived social support (as assessed by 
the Social Support Questionnaire). Both trial groups showed substantial reductions in LIFE-RIFT scores from 
baseline; mean MSSI scores remained below 8 points throughout the trial for both groups, indicating low 
levels of suicidal ideation, and, although perceived social support increased in the RO DBT group, the 
difference between groups was not significant.

The instrumental variables that we incorporated into the design of the study yielded estimates that were 
large, implausible and imprecise. Even conventional analyses, which assume no unobserved confounding, 
were unable to divide the total effect of RO DBT into direct and mediated components. Single-mediator 
models suggested that the pathway, either through learning skills or through therapeutic alliance, had 
had improved participants’ HRSD scores and the all-mediators model suggested that skills had played the 
greater role.

Primary cost-effectiveness analysis showed that the additional cost for RO DBT of £7050 (95% CI £5822 
to £8274; \( p < 0.001 \)) was associated with an increase of 0.032 QALYs (95% CI –0.028 to 0.093 QALYs; 
\( p = 0.30 \)), yielding an incremental cost-effectiveness ratio (ICER) of £220,000 per QALY. This ICER was 
considerably above the willingness-to-pay threshold of £30,000 set by the National Institute for Health and 
Care Excellence (NICE) in the UK, but comparable with ICERs reported for standard dialectical behaviour 
therapy. Hence, from the perspective of the NHS and personal social services, RO DBT was not cost-effective 
relative to TAU alone in treating patients with refractory depression. RO DBT did not achieve sufficient gains 
in QALYs and savings in other health and social services to justify the cost of the resource-intensive therapy 
delivered in this trial. This was true when productivity losses were added.

In total, 33 serious adverse events (SAEs) were reported to the trial manager during the study: four for TAU 
participants, 28 for RO DBT participants and one for a participant before randomisation. It was judged that 
17 SAEs (including all four in the TAU group) were definitely not related to RO DBT, eight were unlikely to 
be related, five were possibly related and three were probably related to RO DBT. Although none of the 
resulting eight possible serious adverse reactions (SARs) was classed as ‘unexpected’, all eight occurred in 
the RO DBT group, which was a statistically significant finding. However, TAU participants were seen by 
trial assessors at only the three follow-up interviews; in contrast, RO DBT participants were seen twice a 
week by trial therapists. We believe that the imbalance in SARs was because of this gross difference in 
reporting opportunities. Indeed, the Data Monitoring and Ethics Committee agreed that there was no 
reason to suspect that RO DBT was harmful.

**Conclusions**

The study found that RO DBT is much more efficacious than TAU in reducing participants’ depressive 
symptoms over the course of treatment. After 7 months of treatment, participants in the RO DBT group 
show significantly fewer depressive symptoms by having an unusually large effect size (Cohen’s \( d \)) with 
a \( d \) of 1.03. Thereafter, TAU patients also showed reductions in symptoms, reducing the effect size to a 
\( d \) of 0.41 at 12 months and a \( d \) of 0.32 at 18 months. Hence, differences between trial groups were not 
statistically significant at 12 or 18 months. However, the mean effect of RO DBT at 12 months reached the 
target effect size with a \( d \) of 0.4 and by exceeding 2 HRSD points, which is generally regarded as clinically 
relevant. Rates of full and partial remission were also consistently higher in RO DBT than TAU participants, 
especially after 7 months. Nevertheless, RO DBT is not cost-effective according to the NICE criteria.
Although the trial participants reported moderate to severe initial depression scores and considerable comorbidity, they reported low to moderate suicidal ideation throughout the study, with no significant differences between groups. Participants in the RO DBT group achieved significantly better psychological flexibility than those in the TAU group at 7, 12 and 18 months, and significantly better emotional approach coping and expressiveness after 7 months, with the difference increasing after 12 and 18 months. This suggests that patients continue to use and improve their RO DBT skills.

However, we could not draw firm conclusions from the analysis using instrumental variables. Standard diagnostics suggested that these variables were weak; therefore, the resulting estimates were biased and unreliable. However, as this was, to our knowledge, the first trial of psychotherapy to allocate instrumental variables at random, the experience will inform others.

**Implications for health care**

This study has demonstrated that depressive symptoms of patients receiving RO DBT decreased significantly during the 7 months of treatment and these reductions in symptoms were maintained at 12 and 18 months. However, the difference between the RO DBT and TAU groups did not achieve statistical significance after 12 and 18 months. This lack of significance was because of, in part, a smaller analysable sample at 12 months than was sought and an improvement in depressive symptoms after 7 months in the TAU group, who received more treatment between months 7 and 12 than the RO DBT group. Despite the higher cost of RO DBT than treatments typically offered within the NHS, it can improve depressive symptoms in a highly symptomatic population who suffer from many mental health problems and PDs and who may require specialised treatment for their problems.

Unlike other treatments for depression, RO DBT does not consider depression to be the primary problem. Instead, RO DBT targets emotional overcontrol – a maladaptive personality style shown to predict the development of chronic internalising disorders, such as resistant depression. Although overcontrolled PDs, including obsessive–compulsive PD, are more common than undercontrolled PDs, patients’ innate capacity to tolerate distress, delay gratification and avoid public displays of emotion make their problems less noticeable. Overcontrolled individuals are likely to play down personal distress when queried and are, therefore, less likely to seek mental health treatment.

**Implications for future research**

The RefraMED trial was the first multisite trial of RO DBT. RO DBT improved depressive symptoms over time, and mediational analyses provided preliminary support for hypothesised mechanisms of change. Future studies should investigate variations on RO DBT that have the potential to be clinically effective but are less costly, for example by reducing the length of treatment or using stepped care that starts with group skills training and reserves one-to-one treatment for non-responsive patients. However, patients such as those who were studied by the RefraMED trial are difficult to treat and unlikely to benefit from short-term solutions. Although the RefraMED trial has investigated some mechanisms underpinning RO DBT, a more thorough investigation of which RO DBT skills are most clinically effective will be critical for developing a shorter version of the treatment, suitable for health-care systems with limited funding.

It is important to develop and test programmes that incorporate feedback from users and, thus, address tapering, online support, ‘graduate groups’ and other forms of continuing support. Given the recurring nature of depression, and the emphasis in RO DBT on changing maladaptive personality, future studies should extend assessment to investigate long-term differences between RO DBT and other treatments. Finally, the transdiagnostic approach of RO DBT supports testing RO DBT across a wider range of conditions, including eating disorders, overcontrolled PDs, anxiety disorders and autism spectrum disorders.
Trial registration

This trial was registered as ISRCTN85784627.

Funding

This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and NIHR partnership.
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

**EME programme**

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

**This report**

The research reported in this issue of the journal was funded by the EME programme as project number 09/150/12. The contractual start date was in September 2011. The final report began editorial review in January 2017 and was accepted for publication in October 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lynch et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).


**NIHR Journals Library Editor-in-Chief**

**Professor Ken Stein**  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** journals.library@nihr.ac.uk